Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease

Página do item simplificado
dc.contributor.authorNascimento M.M.
dc.contributor.authorHayashi S.Y.
dc.contributor.authorRiella M.C.
dc.contributor.authorLindholm B.
dc.date.accessioned2024-03-13T00:59:58Z
dc.date.available2024-03-13T00:59:58Z
dc.date.issued2014
dc.description.abstract© 2014, Associacao Brasileira de Divulgacao Cientifica. All rights reserved.Osteoprotegerin (OPG) regulates bone mass by inhibiting osteoclast differentiation and activation, and plays a role in vascular calcification. We evaluated the relationship between osteoprotegerin levels and inflammatory markers, atherosclerosis, and mortality in patients with stages 3-5 chronic kidney disease. A total of 145 subjects (median age 61 years, 61% men; 36 patients on hemodialysis, 55 patients on peritoneal dialysis, and 54 patients with stages 3-5 chronic kidney disease) were studied. Clinical characteristics, markers of mineral metabolism (including fibroblast growth factor-23 [FGF-23]) and inflammation (high-sensitivity C-reactive protein [hsCRP] and interleukin-6 [IL-6]), and the intima-media thickness (IMT) in the common carotid arteries were measured at baseline. Cardiac function was assessed by color tissue Doppler echocardiography. After 36 months follow-up, the survival rate by Kaplan-Meier analysis was significantly different according to OPG levels (Χ2=14.33; P=0.002). Increased OPG levels were positively associated with IL-6 (r=0.38, P<0.001), FGF-23 (r=0.26, P<0.001) and hsCRP (r=0.0.24, P=0.003). In addition, OPG was positively associated with troponin I (r=0.54, P<0.001) and IMT (r=0.39, P<0.0001). Finally, in Cox analysis, only OPG (HR=1.07, 95%CI=1.02-1.13) and hsCRP (HR=1.02, 95%CI=1.01-1.04) were independently associated with increased risk of death. These results suggested that elevated levels of serum OPG might be associated with atherosclerosis and all-cause mortality in patients with chronic kidney disease.
dc.description.firstpage995
dc.description.issuenumber11
dc.description.lastpage1002
dc.description.volume47
dc.identifier.doi10.1590/1414-431X20144007
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/36354
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsAcesso Aberto
dc.subject.otherlanguageAtherosclerosis
dc.subject.otherlanguageChronic kidney disease
dc.subject.otherlanguageInflammation
dc.subject.otherlanguageMortality
dc.subject.otherlanguageOsteoprotegerin
dc.titleElevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease
dc.typeArtigo
local.scopus.citations34
local.scopus.eid2-s2.0-84923344053
local.scopus.subjectAdolescent
local.scopus.subjectAdult
local.scopus.subjectAged
local.scopus.subjectAged, 80 and over
local.scopus.subjectAtherosclerosis
local.scopus.subjectBiomarkers
local.scopus.subjectBrazil
local.scopus.subjectC-Reactive Protein
local.scopus.subjectCarotid Intima-Media Thickness
local.scopus.subjectCause of Death
local.scopus.subjectEchocardiography, Doppler
local.scopus.subjectFemale
local.scopus.subjectFibroblast Growth Factors
local.scopus.subjectHeart Function Tests
local.scopus.subjectHumans
local.scopus.subjectInterleukin-6
local.scopus.subjectKaplan-Meier Estimate
local.scopus.subjectMale
local.scopus.subjectMiddle Aged
local.scopus.subjectMultivariate Analysis
local.scopus.subjectOsteoprotegerin
local.scopus.subjectRenal Insufficiency, Chronic
local.scopus.subjectRisk
local.scopus.subjectSeverity of Illness Index
local.scopus.subjectYoung Adult
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84923344053&origin=inward
Arquivos
Coleções
Artigos de periódico